Point72 Asset Management
LGND icon

Point72 Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Point72 Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,030
Closed -$2.75M – 1104
2018
Q3 		$2.75M Buy
+16,030
New +$2.42M 0.01% 714

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Point72 Asset Management's LGND Position: Q4 2025 in Review

Point72 Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 16,700 shares — an estimated $2.96M sold.

Point72 Asset Management first reported a position in LGND in Q3 2020 and held it in 6 quarters. The position peaked at $9.62M in Q1 2022. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Point72 Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 16,700 Ligand Pharmaceuticals shares in Q4 2025, an estimated $2.96M.
  • Point72 Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Point72 Asset Management's Ligand Pharmaceuticals position peaked at $9.62M in Q1 2022.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.